Tarsus Historical Income Statement
| TARS Stock | USD 48.24 1.84 3.97% |
Historical analysis of Tarsus Pharmaceuticals income statement accounts such as Selling General Administrative of 84.3 M, Total Revenue of 24.5 M, Other Operating Expenses of 168.6 M or Research Development of 28.9 M can show how well Tarsus Pharmaceuticals performed in making a profits. Evaluating Tarsus Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tarsus Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Tarsus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tarsus Pharmaceuticals is a good buy for the upcoming year.
Tarsus |
About Tarsus Income Statement Analysis
Tarsus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tarsus Pharmaceuticals shareholders. The income statement also shows Tarsus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Tarsus Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tarsus Pharmaceuticals. It is also known as Tarsus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Tarsus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Tarsus Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Tarsus Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tarsus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.At this time, Tarsus Pharmaceuticals' Income Tax Expense is comparatively stable compared to the past year. Gross Profit is likely to gain to about 21 M in 2024, despite the fact that Operating Income is likely to grow to (136 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 312K | 325K | 628K | 659.4K | Total Operating Expenses | 67.1M | 87.6M | 159.0M | 167.0M |
Tarsus Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Tarsus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tarsus Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (40K) | 188K | 36K | 1.3M | 6.4M | 6.8M | |
| Depreciation And Amortization | 368K | 246K | 606K | 789K | 877K | 529.3K | |
| Interest Expense | 40K | 188K | 2.9M | 2.2M | 3.3M | 3.5M | |
| Selling General Administrative | 1.1M | 8.2M | 25.4M | 44.9M | 80.3M | 84.3M | |
| Other Operating Expenses | 4.3M | 27.0M | 69.2M | 88.5M | 160.6M | 168.6M | |
| Operating Income | (4.3M) | (27.0M) | (12.2M) | (62.7M) | (143.2M) | (136.0M) | |
| Net Income From Continuing Ops | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (107.6M) | (102.2M) | |
| Ebit | (4.3M) | (26.8M) | (13.8M) | (59.9M) | (132.5M) | (125.9M) | |
| Research Development | 3.2M | 18.8M | 41.7M | 42.6M | 50.3M | 28.9M | |
| Ebitda | (3.9M) | (26.6M) | (13.2M) | (59.1M) | (131.7M) | (125.1M) | |
| Total Operating Expenses | 4.3M | 27.0M | 67.1M | 87.6M | 159.0M | 167.0M | |
| Reconciled Depreciation | 74K | 246K | 312K | 325K | 628K | 659.4K | |
| Income Before Tax | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (135.9M) | (129.1M) | |
| Total Other Income Expense Net | (371K) | 188K | (1.6M) | 617K | 7.3M | 7.6M | |
| Net Income Applicable To Common Shares | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (55.9M) | (53.1M) | |
| Net Income | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (135.9M) | (129.1M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.